Eli Lilly (LLY 0.38%) has a market capitalization of around $700 billion after soaring 130% over the past 12 months. Investors have become bullish on the company's long-term prospects, particularly with regulators recently approving Zepbound, a weight-loss drug from Eli Lilly that has shown in clinical trials it can help people lose close to 27% of their body weight.Many investors, however, may be worried they have missed the boat on Eli Lilly and that it has become too late to buy the stock given its high ...

Eli Lilly and Company (LLY) has selected Amazon Pharmacy, a subsidiary of Amazon.com (AMZN) , as a third-party dispensing provider for free delivery of its select medicines directly to patients’ homes through its website, LillyDirect. Lilly has a similar partnership with online pharmacy, Truepill.Lilly launched LillyDirect, a new direct-to-consumer website, in January to help patients order medicines for obesity, migraine and diabetes directly from the company via delivery through third-party pharmacies lik ...

Eli Lilly (LLY) closed the latest trading day at $757.84, indicating a +0.38% change from the previous session's end. The stock's change was more than the S&P 500's daily loss of 0.19%. Elsewhere, the Dow gained 0.1%, while the tech-heavy Nasdaq lost 0.54%.The drugmaker's stock has climbed by 1.61% in the past month, falling short of the Medical sector's gain of 2.91% and the S&P 500's gain of 3.18%.The investment community will be paying close attention to the earnings performance of Eli Lilly in its upcom ...

Viking Therapeutics (VKTX 5.77%) shares soared more than 120% in one trading session last month as investors bet on its ability to win in the billion-dollar weight-loss drug market -- or attract a buyer. The biotech company announced positive clinical trial results for its weight-loss candidate that works in the same way as a drug sold by pharma giant Eli Lilly (LLY 2.80%).Patients and investors are excited about this class of drug thanks to impressive results in clinical trials and in the real world. And d ...

Eli Lilly and Company’s (LLY) stock declined 2.3% on Friday after it announced that an FDA decision on its regulatory filing for an important pipeline candidate, donanemab, its anti-amyloid beta antibody for early symptomatic Alzheimer's disease, will be delayed.Donanemab biologics license application (BLA) was based on data from the TRAILBLAZER-ALZ 2 confirmatory phase III study. Lilly said an FDA advisory committee will be convened to discuss data from the TRAILBLAZER-ALZ 2 study to get more information a ...

INDIANAPOLIS, March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Ann ...

Eli Lilly and Novo Nordisk have been among the hottest healthcare stocks to own over the past few years. Since 2021, shares of the two companies are up more than 260%, with Eli Lilly now becoming the most valuable publicly traded healthcare company in the world.Eli Lilly's and Novo Nordisk's diabetes and weight loss treatments have grown in popularity as they have helped patients achieve significant weight loss, and that has made investors bullish on the long-term prospects for these stocks.But the anti-obe ...

Pharmaceutical giant Eli Lilly and Company is trying to clear up misconceptions about obesity care as it increases investment in its highly popular weight-loss drugs.  With the latest phase of Lilly's "Get Better" campaign, the company aims to focus the importance of obesity treatment as a disease, and the appropriate use of anti-obesity medications. These drugs have surged in popularity in recent years, due in part to social media and countless celebrities, such as Elon Musk having touted their weight-loss ...

Regardless of your investment style, adding a few pharmaceutical stocks to your portfolio is a great idea. These players offer you a certain amount of stability because, no matter what's happening in the general economy, people always need their medicines. This generally translates into steady earnings growth for these companies, and pharma companies often share the rewards with investors by offering dividends too.But pharma giants aren't only about stability. Certain companies also may offer you a signific ...

Eli Lilly (LLY -2.31%) stock was on quite a roll this young year, but a new development shifted that momentum on Friday. The shares fell as much as 3.2% in price on Friday afternoon, following the news that a top regulator is delaying a decision on one of the company's most important drug candidates.FDA decision on Alzheimer's drug delayedThat regulator is none other than the U.S. government's powerful Food and Drug Administration (FDA). On Friday, Eli Lilly said that the FDA has unexpectedly pushed back it ...